Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 20/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.88 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.87 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586620 | 0.94 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL6584584 | 0.93 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL6585122 | 0.93 | ADRA1D (0.90) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6584757 | 0.92 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL6585671 | 0.91 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL8010672 | 0.88 | ADRA1D (0.84) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6586285 | 0.88 | ADRA1D (1.00) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6587554 | 0.88 | ADRA1D (0.82) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6586361 | 0.88 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL6586679 | 0.87 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056720-B1 | PHTALIMIDO ARYLPIPERAZINES AS ALPHA 1A RECEPTOR ANTAGONISTS USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ORTHO MCNEIL PHARM INC (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1346983-A2 | Phthalimido arylpiperazines as alpha 1A receptor antagonists useful in the treatment of benign prostatic hyperplasia | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030088099-A1 | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia | KUO GEE-HONG (US) | 2003-05-08 | — | — | US | claimed |
| US-20020077476-A1 | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia | KUO GEE-HONG (US) | 2002-06-20 | — | — | US | claimed |
| EP-1056720-A1 | PHTALIMIDO ARYLPIPERAZINES AS ALPHA 1A RECEPTOR ANTAGONISTS USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| US-6063785-A | ISOMERS OF DRUGS FOR RACEMIC MIXTURES | ORTHO-MCNEIL PHARMACEUTICAL INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999042445-A1 | PHTALIMIDO ARYLPIPERAZINES AS ALPHA 1A RECEPTOR ANTAGONISTS USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-08-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077476-A1 | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia | ADRB1, ADRA1A, ADRA1D | ADRA1D 3/4885ADRA1A 2/4885ADRA1B 4/4885 |
| US-20030088099-A1 | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia | ADRB1, ADRA1A, ADRA1D | ADRA1D 3/4885ADRA1A 2/4885ADRA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.